Unknown

Dataset Information

0

Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.

ABSTRACT: The use of pharmacogenomic biomarkers can enhance treatment outcomes. Regulatory polymorphisms are promising biomarkers that have proven difficult to uncover. They come in two flavors: those that affect transcription (regulatory single-nucleotide polymorphisms (rSNPs)) and those that affect RNA functions such as splicing, turnover, and translation (termed structural RNA SNPs (srSNPs)). This review focuses on the role of srSNPs in drug metabolism, transport, and response. An understanding of the nature and diversity of srSNPs and rSNPs enables clinical scientists to evaluate genetic biomarkers.

SUBMITTER: Sadee W 

PROVIDER: S-EPMC3251919 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.

Sadee W W   Wang D D   Papp A C AC   Pinsonneault J K JK   Smith R M RM   Moyer R A RA   Johnson A D AD  

Clinical pharmacology and therapeutics 20110202 3

The use of pharmacogenomic biomarkers can enhance treatment outcomes. Regulatory polymorphisms are promising biomarkers that have proven difficult to uncover. They come in two flavors: those that affect transcription (regulatory single-nucleotide polymorphisms (rSNPs)) and those that affect RNA functions such as splicing, turnover, and translation (termed structural RNA SNPs (srSNPs)). This review focuses on the role of srSNPs in drug metabolism, transport, and response. An understanding of the  ...[more]

Similar Datasets

Unknown Cardiovascular pharmacogenomics and individualized drug therapy.
| S-EPMC3108370 | biostudies-literature
Transcriptomics Pharmacogenomics of IFNb therapy
2008-04-01 | E-GEOD-10655 | biostudies-arrayexpress
Transcriptomics Pharmacogenomics of IFNb therapy
2008-04-01 | GSE10655 | GEO
Unknown CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
| S-EPMC4082739 | biostudies-other
Transcriptomics Expression data for pharmacogenomics antiplatelet therapy
2012-09-15 | E-GEOD-32226 | biostudies-arrayexpress
Transcriptomics Expression data for pharmacogenomics antiplatelet therapy
2012-09-15 | GSE32226 | GEO
Unknown Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.
| S-EPMC2860269 | biostudies-literature
Unknown Copy number polymorphisms and anticancer pharmacogenomics.
| S-EPMC3219969 | biostudies-literature
Unknown Pharmacogenomics of adverse drug reactions.
| S-EPMC3707028 | biostudies-literature
Unknown Pharmacogenomics of GPCR Drug Targets.
| S-EPMC5766829 | biostudies-literature